Wall St Engine(@wallstengine):Novartis $NVS raised its 2026 core operating income guidance despite booking a $1.9 billion write-down tied to a setback in its del-desiran drug trial. The company now expects core operating income to be flat to up low single digits, compared with its previous forecast for a decline. Q3 revenue rose 4% to $14.5B, while reported operating income fell 59%. CEO Vas Narasimhan defended the company's acquisition strategy, saying, “We don't need to change our M&A strategy.”

Wall St Engine

@wallstengine

Fast, accurate, consistent stock market news, earnings highlights & more. By Brillinsight. Not financial advice.

가입 March 2022

995 팔로잉 중 214.3K 팬

Wall St Engine@wallstengine

2026.10.27 10:29

Novartis $NVS raised its 2026 core operating income guidance despite booking a $1.9 billion write-down tied to a setback in its del-desiran drug trial. The company now expects core operating income to be flat to up low single digits, compared with its previous forecast for a decline. Q3 revenue rose 4% to $14.5B, while reported operating income fell 59%. CEO Vas Narasimhan defended the company's acquisition strategy, saying, “We don't need to change our M&A strategy.”